Community Pharmacy Residency
Dylan Madison is a 2025 graduate of the UF College of Pharmacy, where he earned his Doctor of Pharmacy degree. Throughout his pharmacy education, he developed a strong interest in the outpatient setting, with a particular focus in retail, independent and ambulatory care pharmacy. He is passionate about patient-centered care, building long-term therapeutic relationships and empowering individuals through medication education and adherence support.
Halle Tukes, Pharm.D., joins the University of Florida College of Pharmacy as a PGY1 Community-Based Pharmacy Resident, where she is mentored by Stacey Curtis, Pharm.D. Her community pharmacy practice site is Baya Pharmacy in Lake City, Florida. A native of Georgia, Halle was born in Macon and raised in Quitman. She earned her Doctor of Pharmacy degree from the University of Georgia, following her undergraduate degree at Fort Valley State University. She is professionally interested in academia, ambulatory care and independent pharmacy ownership. Outside of her professional pursuits, Tukes enjoys spending quality time with friends and family, building LEGO sets and baking.
Clinical Pharmacogenetics Fellows
Wandyenid Márquez Moyeno is a pharmacist from Puerto Rico, starting in the Clinical Pharmacogenetics Fellowship. She is passionate about advancing precision medicine to better serve diverse and underrepresented populations. In her free time, she cares deeply about movement and mindful living, practicing CrossFit, yoga, cycling and running. She is incredibly excited to be starting this new chapter in Gainesville and to join a community that is leading the way in pharmacogenetics. She looks forward to learning, growing and contributing to a future where personalized medicine becomes the standard of care.
Milan Scott is a South Florida native of Jamaican descent with a passion for pharmacogenomics and personalized medicine. She holds a bachelor’s degree in biology from Florida Atlantic University and earned her Pharm.D. from the University of Florida College of Pharmacy. She completed a PGY1 residency at Howard University Hospital, where she enhanced and expanded her clinical expertise as a pharmacist. Outside of pharmacy, she is a dedicated music collector with a personal archive of vinyl, CDs and cassettes.
Clinical Research in Community Oncology Fellowship
Lauren Carpenter, Pharm.D., is a 2025 graduate of the UF College of Pharmacy, based on the Jacksonville campus. She earned her Bachelor of Science in Biology from Florida State University in 2021. Recently, she accepted a position as a post-doctoral pharmacy fellow in the newly launched Clinical Research in Community Oncology Fellowship, a collaboration led by UF starting this summer. Carpenter’s clinical interests include pediatrics, hematology/oncology — particularly gastrointestinal, gynecological and cutaneous malignancies as well as ambulatory care. Her research background, as a retrospective cohort sub-investigator, primarily focuses on breast cancer and hematologic disorders such as myelofibrosis and myelodysplastic syndrome.
Kelli Corona, Pharm.D., is an incoming fellow to the Clinical Research in Community Oncology Fellowship program that will be a collaboration between the UF College of Pharmacy and Cancer Specialists of North Florida. She earned her bachelor’s degree in biology from Florida State University and graduated this spring from the UF College of Pharmacy after studying at the Jacksonville campus. Corona’s professional interests lie in oncology and pharmacogenomics, where she aspires to make a meaningful impact in improving cancer treatment and advancing the understanding of personalized medicine in oncology care.
Fellowship in Healthcare Quality, Medication Safety, and Population Health
Jorge A. Valedón Navarro graduated from the University of Florida College of Pharmacy in May of 2025, where he earned his PharmD. He earned his bachelor’s in science in Cellular and Molecular Biology, magna cum laude, from the University of Puerto Rico. Navarro co-founded and serves as vice president of Proyecto Metamorfosis Puerto Rico, a nonprofit supporting individuals with disabilities, and has directed significant funds to community initiatives. He has extensive pharmacy experience at Publix, CVS, Walgreens and Cleveland Clinic. While in college, he participated in clinical research focused on pharmacogenetics and underserved populations. Recognized for his leadership, Navarro served as Student Council President at the Gainesville campus and has received multiple honors, including first place in the local P&T Competition, second place nationally in the LEAP at Eli Lilly Business Competition and the Dean’s Excellence Award during his graduation.
PARADIGM
Andrew Brock, Ph.D., focuses his research on the development of personalized 3D pancreas organoids derived from endoscopic ultrasound (EUS)-guided biopsies. To address interpatient heterogeneity in pancreatic ductal adenocarcinoma (PDAC), he aims to establish a biobank of patient-derived PDAC organoids using fine needle aspirates obtained through EUS-guided core needle biopsies. As part of the PARADIGM postdoctoral training program, Brock will investigate the hypothesis that transcriptomic signatures from personalized patient-derived organoids — both before and after drug screening — can inform precision medicine strategies for PDAC, including treatment selection and early response detection. These organoid cultures will be screened to identify the most effective therapeutic agents, combinations, dosages, and treatment schedules for each individual patient. This information will guide personalized treatment decisions. Future studies will explore whether post-treatment transcriptomic analysis of organoids can identify biomarkers predictive of successful therapeutic outcomes, addressing the current limitations in the timely evaluation of treatment efficacy during critical stages of disease progression.
Jean Malave, Pharm.D., joined the Department of Pharmacotherapy and Translational Research as a Ph.D. student after earning his Pharm.D. from UF. His research focuses on evaluating the impact of clinical, genetic, and social determinants on P2Y12 inhibitor response following percutaneous coronary intervention. Malave’s long-term goal is to identify actionable factors to guide personalized P2Y12 inhibitor prescribing and to identify patient populations that may benefit most from pharmacogenetic testing.
Maksymilian Pilecki, Ph.D., is a third-year general surgery resident at UF and a doctoral student in the Biomedical Sciences Program. He aspires to pursue a fellowship in complex general surgical oncology following the completion of his residency. His professional vision is rooted in the integration of clinical excellence and scientific innovation to improve outcomes for patients with cancer. Pilecki is particularly interested in pancreatic cancer tumor immunology and the epigenetic regulation of the tumor immune microenvironment, where he aims to contribute to the evolving landscape of cancer biology. His long-term goal is to build a career that bridges patient care and translational research, fostering meaningful advancements in oncologic treatment. Through this dual commitment, he seeks to play a role in shaping the future of personalized cancer therapy.
Peter Ramdhan, Pharm.D., joined the Department of Medicinal Chemistry as a Ph.D. student after earning his Pharm.D. from UF. His research focuses on integrating quantum chemistry and molecular dynamics to study the effects of genetic mutations on drug metabolism, with a particular emphasis on CYP2C19 and Clopidogrel. His long-term goal is to develop an AI model that incorporates detailed structural and quantum chemical analyses to improve the accuracy and reliability of CYP variant-drug response predictions. He ultimately aims to translate insights from this model into a framework that can guide in vitro functional studies, improving personalized medicine and drug safety.